Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Eplerenone on Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetic Patients
2011-006123-37Phase 2Completed
- Sponsor
- Solvotrin Therapeutics
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of eplerenone in left ventricular diastolic dysfunction (LVDD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Solvotrin Therapeutics. Primary endpoint: Change in Left Atrial Volume Index (LAVI). Started Mar 2012; status: completed.
02
Drugs
eplerenone
03
Conditions
left ventricular diastolic dysfunction (LVDD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-006123-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006123-37.